Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.39 |
| ▸ | CDK9 | P50750 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870676 | 0.85 | TSHR (0.45) | TSHRALDH1A1NPY5RPOLBMAPT | |
| SCHEMBL5454309 | 0.83 | SKP2 (0.47) | CYP3A4HDAC1CCNT1CDK9TSHR | |
| SCHEMBL2032181 | 0.81 | HDAC1 (0.42) | HDAC1CCNT1CDK9TSHRTLR8 | |
| SCHEMBL9279523 | 0.81 | HDAC1 (0.42) | HDAC1CCNT1CDK9TSHRTLR8 | |
| SCHEMBL2029808 | 0.80 | ALDH1A1 (0.56) | CYP3A4HDAC1CCNT1CDK9TSHR | |
| SCHEMBL2030320 | 0.80 | ALDH1A1 (0.51) | HDAC1CCNT1CDK9TLR8TLR7 | |
| SCHEMBL1509008 | 0.78 | BTK (0.35) | CCNT1CDK9TSHRBTKNPY5R | |
| SCHEMBL3375825 | 0.77 | TSHR (0.50) | HDAC1CCNT1CDK9TSHRTLR8 | |
| SCHEMBL1867715 | 0.77 | TSHR (0.45) | CYP3A4CCNT1CDK9TSHRALDH1A1 | |
| SCHEMBL29470071 | 0.77 | TSHR (0.45) | CYP3A4CCNT1CDK9TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646448-B1 | MACROCYCLIC KINASE INHIBITORS | OSI PHARMACEUTICALS LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9133224-B2 | Macrocyclic kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2646448-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20130261086-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2012074951-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-5770615-A | Catecholamine surrogates useful as β3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-06-23 | — | — | US | disclosed |
| WO-1997037646-A1 | CATECHOLAMINE SURROGATES USEFUL AS β3 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261086-A1 | MACROCYCLIC KINASE INHIBITORS | PTK2, SRC, PTK2B | CYP3A4 2521/4885HDAC1 423/4885CCNT1 632/4885 |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | CYP3A4 3332/4885HDAC1 1897/4885CCNT1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.